Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.
The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.
The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.
A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.
Shares of the company were up over 5.4% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。